The report provides a detailed analysis essential for establishing a Thalidomide production plant. It encompasses all critical aspects necessary for Thalidomide production, including the cost of Thalidomide production, Thalidomide plant cost, Thalidomide production costs, and the overall Thalidomide production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Thalidomide production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Thalidomide is an oral immunomodulatory, anti-inflammatory, and anti-angiogenic medication. It works by blocking a harmful protein called TNF-α that fuels inflammation. It changes how immune cells stick and move, and stops blood vessel growth factors. It is an FDA-approved first-line treatment of newly diagnosed multiple myeloma in combination with dexamethasone or melphalan.
It slows down cancer cell growth and improves survival, as well as acute management and maintenance therapy for moderate to severe erythema nodosum leprosum (ENL) reactions in leprosy patients. It is also used for second-line therapy for graft-versus-host disease (GVHD) post-bone marrow transplant, aphthous stomatitis and wasting syndrome in HIV patients. Its common side effects include drowsiness or sleepiness, dizziness, constipation, dry skin or rash, swelling (edema), fatigue or weakness, headache, nausea, etc.
The market for Thalidomide is driven by the rising incidence of multiple myeloma. Its usage in the treatment of leprosy, autoimmune disorders, and cancers, along with ageing populations and expanded oncology/immunology applications, boosts its demand. The clinical trials for new indications like GVHD and Crohn's, government funding for rare diseases, and healthcare infrastructure growth boost its demand.
The industrial Thalidomide procurement is affected by strict REMS/S.T.E.P.S. regulatory programs because of teratogenic risks, mandating pregnancy testing and patient registries. Also, high costs and limited access for monitoring side effects, along with reliance on licensed generics, limit its sourcing.
Raw Material for Thalidomide Production
According to the Thalidomide production plant project report, the key raw materials used in the production of Thalidomide include Phthalic Anhydride-(L-Glutamine)-Triethylamine.
Production Process of Thalidomide
The extensive Thalidomide production cost report consists of the following major industrial production process:
- From Phthalic Anhydride and L-Glutamine: The production process of Thalidomide starts with grinding phthalic anhydride and L-glutamine. This mixture is suspended in toluene, followed by adding triethylamine and acetic anhydride and refluxed. After reflux, the reaction cools to room temperature, followed by vacuum filtration and washing with saturated sodium bicarbonate solution in water and diethyl ether. The crude Thalidomide solid is dried under vacuum to get pure Thalidomide as the final product.
Thalidomide is a white crystalline solid with molecular formula C13H10N2O4 and a molecular weight of 258.23 g/mol. It has a melting point of 269-271 degree Celsius and a boiling point of 401 degree Celsius. It has a density of 1.29 g/cm³ and a refractive index of 1.53. It has low water solubility but is soluble in 2-hydroxypropyl-β-cyclodextrin and organic solvents. It shows λmax at 300 nm and pKa value of 10.7. It is stable under room temperature in dark, sealed, dry conditions, incompatible with strong oxidants. It exists as a racemic mixture of (R)- and (S)-enantiomers and is combustible and hazardous. It is toxic if swallowed, skin contact, or is used during pregnancy because of teratogenicity.
